leisure time -WSS

leisure time

author：leisure time 2025-09-10 08:41:16 - browse：9

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： STAT wants to know your pick for a great summer read or listen

WSS

Large hospital system sues Multiplan for low

How Robert F. Kennedy Jr. distorted vaccine science

Being 'nonadherent' patient made me a more empathetic doctor

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

White House drug shortages task force keeps mum with Congress

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Hubble vs. James Webb telescope images: See the difference

Drug repurposing or repositioning? The language matters

Undocumented workers face uncertainty as immigration law takes effect in Florida

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Being 'nonadherent' patient made me a more empathetic doctor

How to save PrEP access — and even expand it

Beware reading your test results before your doctor does

Hepatitis C has a cure — but many Americans still lack access to it

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

knowledge

Covid's long

Undocumented workers face uncertainty as immigration law takes effect in Florida

Some of the ways extreme heat will change life as we know it

Novo acquires Inversago for up to $1 billion

After John Oliver segment, STAT readers share their opioid

Newly revealed memo details efforts to keep Trump in power following election loss

entertainment

knowledge

explore

focus